Kyaw Kyaw Hoe, Swane Rowe-Gardener, Thant Hnin Saint Hoe
{"title":"Is furosemide a nephrotoxic for hospitalized patients?","authors":"Kyaw Kyaw Hoe, Swane Rowe-Gardener, Thant Hnin Saint Hoe","doi":"10.34172/jrip.2023.32164","DOIUrl":null,"url":null,"abstract":"Introduction: Acute kidney disease (AKI) is preventable in certain situations. Long-term and/or high dose furosemide may lead to acute kidney injury. Objectives: We aimed to find the risk of AKI among hospitalised patients who were exposed to furosemide. Patients and Methods: This is a retrospective cohort study of hospitalised patients who received furosemide therapy during the admission between 2019 and 2021. Exposure to furosemide was grouped into low dose (≤ 40 mg/d) or high dose (>40 mg/d) and short-term use (≤ 72 hours) or long-term use (>72 hours). Risk of acute kidney injury was calculated as odds ratios with a 95% confidence interval (CI). A P value <0.05 was considered statistically significant. Results: Of 314 patients who received furosemide intravenously or orally, 197 patients (62.7%) had acute kidney injury. Of 197 patients with acute kidney injury, 110 patients (55.9%) received the dosage of >40 mg/d and 121 patients (61.4%) were on furosemide for >7 days (odds ratios [ORs]: 5.46, 95% CI: 3.17 to 9.39, P≤0.001 and ORs: 7.72, 95% CI: 4.4 to 13.52, P≤0.001). In comparison, the 87 (44.1%) patients who received ≤40 mg/d of furosemide had a lower incidence of AKI (ORs: 0.25, 95% CI: 0.13 to 0.48, P≤0.001) and only 21 of the patients (10.6%) who received furosemide for < 7 days were found to have acute kidney injury (ORs: 0.08, 95% CI: 0.04 to 0.14, P≤0.001). The combined effect of high dose and long-term furosemide therapy is more consequential as we found that 100 (31.8%) patients who received furosemide >40 mg for >72 hours, 96 patients (30.6%) developed AKI (ORs: 26.8, 95% CI: 9.53 to 75.63, P≤0.001). Conclusion: Among hospitalised patients, exposure to high dose furosemide or prolonged use of furosemide is associated with AKI. The risk is more when high dose furosemide is administered for longer than 72 hours. Presence of underlying diabetes, hypertension, cardiac failure and chronic kidney disease, are also associated with furosemide -induced hospital-acquired acute kidney injury.","PeriodicalId":16950,"journal":{"name":"Journal of Renal Injury Prevention","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2023-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Renal Injury Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jrip.2023.32164","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Acute kidney disease (AKI) is preventable in certain situations. Long-term and/or high dose furosemide may lead to acute kidney injury. Objectives: We aimed to find the risk of AKI among hospitalised patients who were exposed to furosemide. Patients and Methods: This is a retrospective cohort study of hospitalised patients who received furosemide therapy during the admission between 2019 and 2021. Exposure to furosemide was grouped into low dose (≤ 40 mg/d) or high dose (>40 mg/d) and short-term use (≤ 72 hours) or long-term use (>72 hours). Risk of acute kidney injury was calculated as odds ratios with a 95% confidence interval (CI). A P value <0.05 was considered statistically significant. Results: Of 314 patients who received furosemide intravenously or orally, 197 patients (62.7%) had acute kidney injury. Of 197 patients with acute kidney injury, 110 patients (55.9%) received the dosage of >40 mg/d and 121 patients (61.4%) were on furosemide for >7 days (odds ratios [ORs]: 5.46, 95% CI: 3.17 to 9.39, P≤0.001 and ORs: 7.72, 95% CI: 4.4 to 13.52, P≤0.001). In comparison, the 87 (44.1%) patients who received ≤40 mg/d of furosemide had a lower incidence of AKI (ORs: 0.25, 95% CI: 0.13 to 0.48, P≤0.001) and only 21 of the patients (10.6%) who received furosemide for < 7 days were found to have acute kidney injury (ORs: 0.08, 95% CI: 0.04 to 0.14, P≤0.001). The combined effect of high dose and long-term furosemide therapy is more consequential as we found that 100 (31.8%) patients who received furosemide >40 mg for >72 hours, 96 patients (30.6%) developed AKI (ORs: 26.8, 95% CI: 9.53 to 75.63, P≤0.001). Conclusion: Among hospitalised patients, exposure to high dose furosemide or prolonged use of furosemide is associated with AKI. The risk is more when high dose furosemide is administered for longer than 72 hours. Presence of underlying diabetes, hypertension, cardiac failure and chronic kidney disease, are also associated with furosemide -induced hospital-acquired acute kidney injury.
期刊介绍:
The Journal of Renal Injury Prevention (JRIP) is a quarterly peer-reviewed international journal devoted to the promotion of early diagnosis and prevention of renal diseases. It publishes in March, June, September and December of each year. It has pursued this aim through publishing editorials, original research articles, reviews, mini-reviews, commentaries, letters to the editor, hypothesis, case reports, epidemiology and prevention, news and views and renal biopsy teaching point. In this journal, particular emphasis is given to research, both experimental and clinical, aimed at protection/prevention of renal failure and modalities in the treatment of diabetic nephropathy. A further aim of this journal is to emphasize and strengthen the link between renal pathologists/nephropathologists and nephrologists. In addition, JRIP welcomes basic biomedical as well as pharmaceutical scientific research applied to clinical nephrology. Futuristic conceptual hypothesis that integrate various fields of acute kidney injury and renal tubular cell protection are encouraged to be submitted.